Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study

Hemoglobin

Volumn 27, Issue 2, 2003, Pages 63-76

  Galia, Massimo ^a   Midiri, Massimo ^a   Bartolotta, Vincenzo ^a   Morabito, Alberto ^b   Rizzo, Michele ^c   Mangiagli, Antonino ^d   Malizia, Roberto ^e   Borsellino, Zelia ^f   Capra, Marcello ^f   D'Ascola, Domenico G ^g   Magnano, Carmelo ^h   Gerardi, Calogera ⁱ   Rigano, Paolo ^j   Maggio, Aurelio ^j  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Centro Microcitemia   (Italy)

^d Centro Microcitemia   (Italy)

^e Ospedale Villa Sofia   (Italy)

^f Ospedale dei Bambini G Di Cristina   (Italy)

^g Ospedale Civile   (Italy)

^h GARIBALDI HOSPITAL   (Italy)

ⁱ Ospedale Civile   (Italy)

^j UO Ematologia II con Talassemia   (Italy)

more..

Author keywords

Deferiprone (L1); Deferoxamine B mesylate (DF); Heart; Heart to muscle signal intensity ratio(s) HSIR(s) ; Liver iron concentration (LIC); Magnetic resonance imaging (MRI); Myocardial iron overload; Signal intensity ratio(s) SIR(s)

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IRON;

ADOLESCENT; ADULT; ARTICLE; BIOACCUMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EVALUATION; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART MUSCLE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PARAMETER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; BETA-THALASSEMIA; DEFEROXAMINE; FEMALE; HEART FUNCTION TESTS; HUMANS; INFUSIONS, PARENTERAL; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PATIENT COMPLIANCE; PYRIDONES;

EID: 10744221241     PISSN: 03630269     EISSN: None     Source Type: Journal    
DOI: 10.1081/HEM-120021538     Document Type: Article

References (39)

1. Oliveri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331:574-578.
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-573.
3. Jacobs A. The pathology of iron overload. In: Jacobs A, Worwood M, eds. Iron in Biochemistry and Medicine, II. New York: Academic Press, 1980:439-452.
4. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76:435-444.
5. Orton R, Veber L, Sulh II. Ocular and auditory toxicity of high dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20:153-156.
6. Piga A, Luzzato L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High-dose deferoxamine as a cause of growth failure in thalassaemic patients. Eur J Haematol 1988; 40:380-381.
7. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Haematol 1992; 54:371-374.
8. Tenenbein M, Kowalsky S, Sienko A, Bowden DH, Adamson IYR. Pulmonary toxic effects of continuous deferoxamine administration in acute iron poisoning. The Lancet 1992; 339:669-704.
9. Hoffbrand AV, Wonke B. Iron chelation therapy. J Int Med 1997; 242:37-41.
10. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola GD, Rizzo A, Midiri M. Deferiprone versus Deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28:196-208.
11. Crosby WH. Serum ferritin fails to indicate hemochromatosis: nothing gold can stay. N Engl J Med 1976; 294:333-334.
12. Green R, Watson LR, Saab GA, Crosby WH. Normal serum ferritin: a caution. Blood 1977; 50:545-547.
13. Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and non haem (storage) iron distribution. Arch Pathol Lab Med 1987; 11:549-554.
14. Ludwig J, Batts KP, Moyer TP, Baldus WP, Fairbanks VF. Liver biopsy diagnosis of homozygous hemochromatosis: a diagnostic algorithm. Mayo Clin Proc 1993; 68:263-267.
15. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997; 41:115-120.
16. Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver. Semin Diagn Pathol 1998; 15:237-245.
17. Gomori JM, Horev G, Tamary H, Zandback J, Kornreich L, Zaizov R, Freud E, Krief O, Ben-Meier J, Rotem H. Hepatic iron overload: quantitative MR imaging. Radiology 1991; 179:367-369.
18. Gandon Y, Guyader D, Heautot JF, Reda MI, Yaouanq J, Buhe T, Brissot P, Carsin M, Deugnier Y. Haemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193:533-538.
19. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol 1994; 87:171-184.
20. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol 1995; 89:880-889.
21. Siegelman ES, Mitchell DG, Semelka R. Abdominal iron deposition: metabolism, MR findings, and clinical importance. Radiology 1996; 199:13-22.
22. Johnston DL, Rice L, Vick GW, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989; 87:40-47.
23. Midiri M, Gallo C, Finazzo M, Maggio A, Morabito A, Castelli F, Lagalla R. The liver in patients with β-thalassemia major. Determination of iron concentration with magnetic resonance imaging. Radiol Med 1999; 97:60-65.
24. Stark DD, Moseley ME, Bacon MR, Moss AA, Goldberg HI, Bass NM, James TL. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985; 154:137-142.
25. Midiri M, Lo Casto A, Sparacia GV, Malizia R, D'Angelo P, De Maria M, Lagalla R. MR imaging of pancreatic changes in patients with transfusion dependent β-thalassemia major. Am J Radiol 1999; 173:187-192.
26. Siegelman ES, Mitchell DG, Rubin R, Hann HW, Kaplan KR, Steiner RM, Rao VM, Schuster SJ, Burk DL Jr, Rifkin MD. Parenchymal versus reticuloendothelial iron overload in the liver: distinction with MR imaging. Radiology 1991; 179:361-366.
27. Sparacia G, Midiri M, D'Angelo P, Lagalla R. Magnetic resonance imaging of the pituitary gland in patients with secondary hypogonadism due to transfusional hemochromatosis. MAGMA 1999; 8:87-90.
28. Argyropoulou MI, Metafratzi Z, Kiortsis DN, Bitsis S, Tsatsoulis A, Efremidis S. T2 relaxation rate as an index of pituitary iron overload in patients with β-thalassemia major. Am J Radiol 2000; 175:1567-1569.
29. Liu P, Henkelman M, Joshi J, Hardy P, Butany J, Iwanochko M, Clauberg M, Dhar M, Mai D, Waien S, Olivieri NF. Quantification of cardiac and tissue iron by nuclear magnetic resonance in a novel murine thalassemia-cardiac iron overload model. Can J Cardiol 1996; 19:155-164.
30. Mavrogeni SI, Maris T, Gouliamos A, Vlahos L, Kremastinos DT. Myocardial iron deposition in β-thalassemia studied by magnetic resonance imaging. Int J Cardiac Imag 1998; 14:117-122.
31. Jensen PD, Jensen FT, Christensen T, Heickendorff L, Jensen LG, Ellegaard J. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. MAGMA 2001; 12:153-166.
32. Zaino EC, Wielopolski L. In vivo measurement of hepatic and cardiac iron in Cooley's anemia by nuclear resonance scattering. Ann NY Acad Sci 1990; 612:573-576.
33. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennel DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Europ Heart J 2001; 22:2171-2179.
34. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous deferoxamine on myocardial iron concentration and ventricular function in β-thalassaemia. The Lancet 2002; 360:516-520.
35. Richard PJ. King's endomyocardial bioptame. The Lancet 1974; ii:660.
36. Gomori JM, Grossman RI, Drott HR. MR relaxation times and iron content of thalassemic spleens: an in vitro study. Am J Radiol 1988; 150:567-569.
37. Kaltwasser JP, Gottsschalk R, Schalk KP, Hartl W. Non-invasive quantitation of liver iron overload by magnetic resonance imaging. Br J Haematol 1990; 74:360-363.
38. Rocchi E, Cassanelli M, Borghi A, Paolillo F, Pradelli M, Casalgrandi G, Burani A, Gallo E. Magnetic resonance imaging and different levels of iron overload in chronic liver disease. Hepatology 1993; 17:997-1002.
39. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 1989; 42:382-388.